Senseonics Holdings, Inc. (NYSE American: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced plans to participate in the upcoming hybrid H.C. Wainwright Global Investment Conference.
Management is scheduled to participate virtually and hold one on-one-meetings Tuesday, May 24, 2022. An on-demand presentation webcast will be available at the start of the conference on Tuesday, May 24, 2022, at 7:00am ET. Interested parties may access the webcast recording on the “Investors” section of the Company’s website at www.senseonics.com.
Senseonics Holdings, Inc. (“Senseonics”) is a medical technology company focused on the development and manufacturing of glucose monitoring products designed to transform lives in the global diabetes community with differentiated, long-term implantable glucose management technology. Senseonics' CGM systems, Eversense®, Eversense® XL and Eversense® E3 include a small sensor inserted completely under the skin that communicates with a smart transmitter worn over the sensor. The glucose data are automatically sent every 5 minutes to a mobile app on the user's smartphone.